Interestingly, a recent study showed that treatment of ovarian cancer cells with neutralizing IL-6 antibodies resulted in upregulated EGFR, whereas the combination of neutralizing IL-6 antibodies and the EGFR inhibitor gefitinib exhibited enhanced anticancer activity [283]. This evidence concerns the gene IL6 and ovarian cancer.